|
|||||
|
|
Metronidazole in the treatment of metastatic brain tumors |
|
| Authors: | Robert Aiken John M Leavengood Jae-Ho Kim Michael DF Deck Howard T Thaler Jerome B Posner |
| Affiliation: | (1) Department of Neurology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York City, USA;(2) Radiology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York City, USA;(3) Radiation Therapy, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York City, USA;(4) Biostatistics, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York City, USA;(5) Present address: Department of Neurology, Jefferson Medical College, Philadelphia, PA, USA;(6) Present address: 2111 Tyrone Boulevard, St Petersburg, Florida, USA;(7) Present address: 1275 York Avenue, 10021 New York, NY, USA |
| Abstract: | Summary We measured the effect of the radiation enhancer metronidazole on patients with metastatic brain tumors undergoing radiation therapy (RT) in a randomized controlled study. Metronidazole was given in a dose of 6 g/m2 4 h before each of the first 3 doses of RT to the whole-brain. A total of 3000 rad was delivered in 6 doses. Patients were followed by serial neurological examinations and CT scans. The metronidazole group did not differ from the control group when measured in terms of survival, clinical improvement or improvement on CT scan, whether measured 2 months or 6 months following treatment. Nausea and vomiting was a significant side effect, preventing about 10% of patients from completing the treatment. Metronidazole appears to have no substantial radiation enhancing effect on metastatic brain tumors. |
| Keywords: | metronidazole radiation therapy radiation enhancers metastatic brain tumors |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |